SCHEDULE: Adage Capital Discloses 2.38% Stake in Karyopharm

Adage Capital Management, L.P. and its principals reported a 2.38% beneficial ownership stake in Karyopharm Therapeutics Inc. as of December 31, 2025.

Summary

• Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 436,736 shares of Karyopharm Therapeutics Inc. Common Stock.
• This ownership represents 2.38% of the company's outstanding Common Stock.
• The reported shares include 15,414 shares of Common Stock issuable upon the exercise of warrants.
• The percentage is calculated based on 18,310,283 shares of Common Stock outstanding as of December 29, 2025, as reported in Karyopharm's Preliminary Proxy Statement on Schedule 14A.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as slightly positive. While a Schedule 13G is primarily a factual disclosure, the continued beneficial ownership by a prominent institutional investor like Adage Capital Management can be interpreted as a vote of confidence in Karyopharm Therapeutics Inc., suggesting a stable or potentially improving outlook from an investment perspective.

Positives

• The disclosure of a significant institutional stake by Adage Capital Management, L.P., a well-known investment manager, can be viewed as a positive signal of institutional confidence in Karyopharm Therapeutics Inc.

Negatives

• The filing itself does not contain any negative information regarding Karyopharm Therapeutics Inc.'s operations or financial performance.

Risks

• The filing is a beneficial ownership report and does not detail specific risks related to Karyopharm Therapeutics Inc.'s business or operations.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Karyopharm Therapeutics Inc.'s future performance or outlook.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes by major investment firms. While not directly related to operational performance, such disclosures can influence market perception, especially when a reputable firm like Adage Capital Management maintains a position in a biotechnology company like Karyopharm Therapeutics Inc., which operates in a sector often characterized by high R&D costs and regulatory hurdles.

Stakeholder Impact

• Shareholders: The disclosure of institutional ownership by Adage Capital Management may instill confidence among existing shareholders and potentially attract new investors, as it signals institutional interest in Karyopharm Therapeutics Inc.

Key Dates

Keywords

Karyopharm Therapeutics Inc., Adage Capital Management, Beneficial Ownership, Schedule 13G, Institutional Investment, Common Stock, Warrants, Biotechnology